Silver Book Fact

Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of over $472.1 million– in 1994 dollars.

Javitt, Jonathan C., Lloyd Paul Aiello, Yen-Pin Chiang, and S. Greenfield. Preventive Eye Care in People With Diabetes is Cost-Saving to the Federal Government: Implications for health care reform. Diabetes Care. 1994; 17(8): 909-17. http://care.diabetesjournals.org/cgi/content/abstract/17/8/909

Reference

Title
Preventive Eye Care in People With Diabetes is Cost-Saving to the Federal Government: Implications for health care reform
Publication
Diabetes Care
Publication Date
1994
Authors
Javitt, Jonathan C., Lloyd Paul Aiello, Yen-Pin Chiang, and S. Greenfield
Volume & Issue
Volume 17, Issue 8
Pages
909-17
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Timely treatment and follow-up care can reduce the risk of blindness in individuals with proliferative retinopathy by 95%.  
  • Supplementation with lutein increases macular pigment optical density by 27%; which is correlated with benefits in visual function.  
  • The cost-effectiveness of detection and treatment of eye disease in diabetics is $3,190 per quality adjusted life year (QALY).  
  • Tele-ophthalmology
    Adequately trained general practitioners can screen for DR with 90% sensitivity using tele-ophthalmology.  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.